uploads/2018/02/Simponi.png

Johnson & Johnson’s Simponi Could See Steady Growth in 2018

By

Updated

Simponi’s revenue trends

In fiscal 2017, Johnson & Johnson’s (JNJ) Simponi generated revenues of $1.8 billion, which reflected ~5.0% growth on a year-over-year (or YoY) basis.

In 2017, in the US market and in international markets, Simponi generated revenues of $954.0 million and $879.0 million, respectively, compared to $959.0 million and $786.0 million in 2016, reflecting an ~0.5% decline and ~12.0% growth on a YoY basis.

In 4Q17, Simponi generated revenues of $490.0 million, which is ~15.0% growth on a YoY basis and 3.0% growth quarter-over-quarter.

In 4Q17, in the US market and international markets, Simponi generated revenues of $253.0 million and $237.0 million, respectively, compared to $243.0 million and $183.0 million in 4Q16, which is ~4.1% and ~29.5% growth on a YoY basis.

Article continues below advertisement

Recent developments

In October 2017, the FDA approved Simponi Aria (golimumab) for the treatment of adult individuals with active psoriatic arthritis or active ankylosing spondylitis.

Johnson & Johnson conducted the pivotal Phase 3 GO-VIBRANT trial to evaluate the safety and efficacy of Simponi in the treatment of adult individuals with active psoriatic arthritis who are biologic-naïve.

Johnson & Johnson’s press release on October 20, 2017, said, “In the GO-VIBRANT study, 75 percent of patients receiving Simponi Aria, compared with 22 percent of patients receiving placebo, achieved at least a 20 percent improvement in the American College of Rheumatology (or ACR20) response at week 14.”

Johnson & Johnson also conducted a pivotal Phase 3 GO-ALIVE trial, which evaluated the safety and efficacy of Simponi Aria in adult individuals with active ankylosing spondylitis.

Johnson & Johnson’s press release dated October 20, 2017, said, “In the GO-ALIVE study, 73 percent of patients receiving Simponi Aria®, compared with 26 percent of patients receiving, achieved at least a 20 percent improvement in the Assessment of Spondyloarthritis International Society criteria (ASAS20) at week 16.”

To learn more about the results of these clinical trials, please refer to Johnson & Johnson’s release regarding FDA approval of Simponi Aria. The approval of Simponi Aria for the two new indications is expected to boost the sales growth of the drug in 2018.

In the psoriatic arthritis drugs market, Simponi’s peers include Novartis’s (NVS) Cosentyx, Amgen’s (AMGN) Enbrel, and Celgene’s (CELG) Otezla.

Advertisement

More From Market Realist